EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation

Christian T Ruff, Siddharth M Patel iD, Robert P Giugliano, David A Morrow, Bruce Hug, Julia F Kuder, Erica L Goodrich, Shih-Ann Chen, Shaun G Goodman, Boyoung Joung iD, Robert G Kiss, Jindrich Spinar und 8 weitere

New England Journal of Medicine · 23.01.2025 · 392 (4) · 361-371

DOI: 10.1056/nejmoa2406674 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 23.01.2025. Verfasst von Christian T Ruff und 19 weiteren Autor:innen. Beteiligte Einrichtung: From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (C.T.R., S.M.P., R.P.G.,…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Anticoagulants, Atrial Fibrillation, Factor Xa Inhibitors. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Anthos Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAnticoagulantsAtrial FibrillationFactor Xa InhibitorsHemorrhageRivaroxabanAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, OralDouble-Blind MethodFactor XIInjections, SubcutaneousStrokeIncidenceSeverity of Illness IndexFollow-Up StudiesTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedAnticoagulantsFactor Xa InhibitorsFactor XIRivaroxabanabelacimab

Autor:innen und Institutionen

  • From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (C.T.R., S.M.P., R.P.G., D.A.M., J.F.K., E.L.G., S.A.M., S.D.W., M.S.S.); Anthos Therapeutics,…

ORCID-Profile: Siddharth M Patel, Boyoung Joung

Förderung

  • Anthos Therapeutics

Zitieren

APA

Ruff, C. T., Patel, S. M., Giugliano, R. P., Morrow, D. A., Hug, B., Kuder, J. F., Goodrich, E. L., Chen, S. A., Goodman, S. G., Joung, B., Kiss, R. G., Spinar, J., Wojakowski, W., Weitz, J. I., Murphy, S. A., Wiviott, S. D., Parkar, S., Bloomfield, D., Sabatine, M. S., & AZALEA–TIMI 71 Investigators (2025). Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. New England Journal of Medicine, 392(4), 361-371. https://doi.org/10.1056/nejmoa2406674

Vancouver

Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, et al. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2025;392(4):361-371. doi:10.1056/nejmoa2406674

BibTeX
@article{Ruff2025,
  author = {Ruff, Christian T and Patel, Siddharth M and Giugliano, Robert P and Morrow, David A and Hug, Bruce and Kuder, Julia F and Goodrich, Erica L and Chen, Shih-Ann and Goodman, Shaun G and Joung, Boyoung and Kiss, Robert G and Spinar, Jindrich and Wojakowski, Wojciech and Weitz, Jeffrey I and Murphy, Sabina A and Wiviott, Stephen D and Parkar, Sanobar and Bloomfield, Daniel and Sabatine, Marc S and AZALEA–TIMI 71 Investigators, AZALEA–TIMI 71 Investigators},
  title = {Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {4},
  pages = {361--371},
  doi = {10.1056/nejmoa2406674}
}
Kostenlos starten →